Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation

Nature Medicine

Volumn 6, Issue 3, 2000, Pages 313-319

  Galve Roperh, Ismael ^a   Sánchez, Cristina ^a   Cortés, María Luisa ^b   Del Pulgar, Teresa Gómez ^a   Izquierdo, Marta ^b   Guzmán, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID RECEPTOR; CERAMIDE; DRONABINOL; PHOSPHOTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER REGRESSION; CELL CULTURE; DRUG SAFETY; ENZYME ACTIVATION; GLIOBLASTOMA; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CANNABINOIDS; CERAMIDES; DNA-BINDING PROTEINS; GLIOMA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; SPHINGOMYELINS; SPHINGOSINE; TETRAHYDROCANNABINOL; TUMOR CELLS, CULTURED;

ANIMALIA; CANNABIS SATIVA; RATTUS NORVEGICUS;

EID: 17344380844     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/73171     Document Type: Article

References (49)

1. 2 receptors. Pharmacol. Ther. 74, 129-180 (1997).
2. Felder, C.C. & Glass, M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38, 179-200 (1998).
3. Matsuda, L.A., Lolait, S.J., Brownstein, M., Young, A. & Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
4. Munro, S., Thomas, K.L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
5. Devane, W.A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
6. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide. Nature 372, 686-691 (1994).
7. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778 (1997).
8. Childers, S.R. & Breivogel, C.S. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depen. 51, 173-187 (1998).
9. Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528 (1998).
10. Grinspoon, L. & Bakalar, J.B. Marihuana as medicine: a plea for consideration. J. Am. Med. Assoc. 273, 1875-1876 (1995).
11. Voth, E. & Schwartz, R. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann. Intern. Med. 126, 791-798 (1997).
12. De Petrocellis, L. et al The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl. Acad. Sci. USA 95, 8375-8380 (1998).
13. 9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436, 6-10 (1998).
14. Barth, R.F. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74) RT-2 and CNS-1 gliomas. J. Neurooncol 36, 91-102 (1998).
15. Shinkai, Y. et al. RAG-2-Deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867 (1992).
16. Louis, D.N. & Gusella, J.F. A tiger behind many doors: multiple genetic pathways to malignant gliomas. Trends Genet. 11, 412-415 (1995).
17. Maintz, D. et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56, 1098-1104 (1997).
18. Röser, K., Bohn, W., Giese, G. & Mannweiler, K. Subclones of C6 rat glioma cells differing in intermediate filament protein expression. Exp. Cell Res. 197, 200-206 (1991).
19. 3 induces programmed cell death in rat glioma cell line. J. Neurosci. Res. 46, 540-545 (1996).
20. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54, 834-843 (1998).
21. Blázquez, C., Sánchez, C., Daza, A., Galve-Roperh, I. & Guzmán, M. The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme. J. Neurochem. 72, 1759-1768 (1999).
22. Ariga, T., Jarvis, W.D. & Yu, R.K. Role of sphingomyelin-mediated cell death in neurodegenerative diseases. J. Lipid Res. 39, 1-16 (1998).
23. Kolesnick, R.N. & Krönke, M. Regulation of ceramide production and apoptosis. Annu. Rev. Physiol. 60, 643-665 (1998).
24. Marshall, C.J. Taking the Rap. Nature 392, 553-554 (1998).
25. Morrison, D.K. & Cutler, R.E. Jr. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9, 174-179 (1997).
26. Zhang, Y. et al. Kinase supressor of Ras is ceramide-activated protein kinase. Cell 89, 63-72 (1997).
27. Nicotera, P., Leist, M. & Manzo, L. Neuronal cell death: a demise with different shapes. Trends Pharmacol. Sci. 20, 46-51 (1999).
28. Price, D.L. New order from neurological disorders. Nature 399, A3-A5 (1999).
29. Huwiler, A. et al. Ceramide binding and activation defines protein kinase c-raf as a ceramide-activated protein kinase. Proc. Natl. Acad. Sci. USA 93, 6959-6963 (1996).
30. Müller, G. et al. Regulation of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling. EMBO J. 17, 732-742 (1998).
31. Michaud, N.R. et al. KSR stimulates Raf-1 activity in a kinase-independent manner. Proc. Natl. Acad. Sci. USA 94, 12792-12796 (1997) (correction 95, 2714, 1998).
32. Derkinderen, P., Enslen, H. & Girault, J.A. The ERK/MAP-kinases cascade in the nervous system. NeuroReport 10, R24-R34 (1999).
33. Pumiglia, K.M. & Decker, S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad Sci. USA 94, 448-452 (1997).
34. York, R.D. et al. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392, 622-626 (1998).
35. Mohr, S., McCormick, T.S. & Lapetina, E.G. Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: Dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059. Proc. Natl. Proc. Sci. USA 95, 5045-5050 (1998).
36. Murray, B., Alessandrini, A., Cole, A.J., Yee A.G. & Furshpan, E.J. Inhibition of the p42/p44 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc. Natl. Acad. Sci. USA 95, 11975-11980 (1998).
37. Martuza, R.L. Act locally, think globally. Nature Med. 3, 1323 (1997).
38. Laske, D.W., Youle, R.J. & Oldfield, E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. 3, 1362-1368 (1997).
39. Ram, Z. et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. 3, 1354-1361 (1997).
40. Mason, W., Louis, D.N. & Cairncross, J.C. Chemosensitive gliomas in adults: which ones and why? J. Clin. Oncol. 15, 3423-3426 (1997).
41. Avgeropoulos, N.G. & Batchelor, T.T. New treatment strategies for malignant gliomas. Oncologist 4, 209-224 (1999).
42. Skaper, S.D. et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA 93, 3984-3989 (1996).
43. Shen, M. & Thayer, S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459-462 (1998).
44. Nagayama, T. et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995 (1999).
45. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268-8273 (1998).
46. Brotchie, J.M. Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement. Curr. Opin. Neurol. 10, 340-345 (1997).
47. Izquierdo, M. et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther. 2, 66-69 (1995).
48. Cortés, M.L., de Felipe, P., Martín, V., Hughes, M.A. & Izquierdo, M. Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 5, 1499-1507 (1998).
49. Calve-Roperh, I. et al. Evidence for the lack of involvement of sphingomyelin hydrolysis in the tumor necrosis factor-induced secretion of nerve growth factor in primary astrocyte cultures. J. Neurochem. 71, 498-505 (1998).